Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 03, 2025 07:00 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

Entrada Therapeutics announces the appointment of Maha Radhakrishnan, M.D., to its Board of Directors.
June 02, 2025 16:30 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Entrada Therapeutics announces inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4).
May 28, 2025 07:00 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Entrada Therapeutics announces that it has received authorization in the European Union to initiate its ELEVATE-45-201 clinical study.
May 08, 2025 07:00 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics Reports First Quarter 2025 Financial Results

Entrada Therapeutics, Inc. (Nasdaq: TRDA) reports financial results for the first quarter ended March 31, 2025, and highlights recent business updates.
March 24, 2025 07:00 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study
February 27, 2025 07:00 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
February 24, 2025 07:00 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
February 03, 2025 07:00 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

Entrada Therapeutics Receives Authorization in the UK to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44
December 18, 2024 07:00 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
November 05, 2024 07:00 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics Reports Third Quarter 2024 Financial Results

Entrada Therapeutics Reports Third Quarter 2024 Financial Results

Next Page keyboard_arrow_right